cafepharma’s detailpiece

At the Wachovia Healthcare Conference, yesterday, Celgene (NASDQ: CELG)CFO, Dave Gryska, delivered good news for Celgene investors and patients. The company is generating significant cash flows (900 million) and generated $1.4 billion in total revenue. This exceeded guidance at the beginning of ‘07 projecting $1.3 billion. Additionally earnings per share (EPS) for ‘07 of $1.06 […]

At the Wachovia Healthcare Conference yesterday, OSI Pharmaceuticals (NASDAQ: OSIP) discussed Tarceva sales and future plans and strategies. OSI is predicting $2.00 EPS (earnings per share) for 2008 based on the strength of Tarceva sales. This is up from approximately $1.15 EPS for 2007.
Tarceva sales for Q4 2007 were $250 million and tracking at $1 […]

At the Wachovia Securities Healthcare Conference, Onyx Pharmaceuticals (NASDAQ: ONXX) presented recent financial results and information regarding ongoing studies for its lead product, Nexavar. Juliana Woods, VP of Investor Relations discussed financial performance and overall development programs. Henry Fuchs, M.D., discussed clinical trials in more detail. The presentation can be heard in its entirety at: […]

Seattle Genetics (Nasdq: SGEN)announced today that it intends to sell, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering. The underwriters will be granted a 30-day option to purchase up to an additional 1,500,000 shares of the common stock to cover over-allotments.
Information about the offering is available […]

Mochida Pharmaceutical announced today that it has liscenced a portfolio of transient receptor potential vanillion sub type 1 (TRPV1) receptor antagonists - to Wyeth (NYSE: WYE) as a potential novel treatment for pain.   Other potential uses for TRPV1 antagonists currently under investigation include cough and appetite stimulation (Neurogen Corp. & Glaxo SmithKline)
Wyeth will obtain exclusive […]

Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (pink sheets: MYLGF.pk) announced the enrollment of the first patient in a Phase 2 clinical trial (Trial CL002) evaluating MGCD0103. This is the Companies’ isotype-selective histone deacetylase inhibitor (HDACi) product candidate. It will be used in combination with Vidaza (azacitidine for injection), Pharmion’s DNA demethylating agent in patients […]

According to an article on the National Legislative Association on Prescription Drug Prices (NLARx) website, its Chair and Council member, David Catania, was recently named Big Pharma Enemy Number 1. The article states this fact as if it were an official designation like the FBI’s public enemy number 1.
I have been in the pharmaceutical industry […]

Morphotek, Inc a subsidiary of Eisai Co, Ltd, announced today that is has signed a Cooperative Research and Development Agreement (CRDA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers. Morphotek’s proprietary MORPHODOMA(R) antibody technology will be used to develop novel antibodies for use […]

Nektar Therapeutics (NASDAQ: NKTR) announced the start of its Phase 2 clinical development program to evaluate NKTR-102 (PEG-irinotecan) as a potential treatment for colorectal cancer. The molecule is the lead candidate developed with the company’s small molecule PEGylation technology platform.
Nektar President and CEO, Howard Robin said, “The start of the Phase 2 program for NKTR-102 […]

The CEO of Merck and Co. (NYSE: MRK), Richard Clark, said on Thursday that the company’s Vytorin would likely gain future sales from patients that fail to get an adequate response from generic forms of the company’s older cholesterol drug Zocor. Vytorin is a single pill combination of cholesterol lowering drug, Zetia, and Zocor.
Generic Zocor […]